Story
Merck Secures FDA Approval for Lipfendra, First-in-Class Oral PCSK9 Cholesterol Drug
Summary
Merck has received U.S. Food and Drug Administration approval for Lipfendra, the first oral PCSK9 inhibitor for high cholesterol, providing a new revenue source ahead of the patent expiration for its top-selling drug, Keytruda.
Merck (NYSE:MRK) announced Thursday it has received U.S. Food and Drug Administration (FDA) approval for Lipfendra, the first oral PCSK9 inhibitor for the treatment of high cholesterol. The new drug offers a convenient alternative to existing injectable therapies for patients with hypercholesterolemia, a condition marked by elevated levels of LDL cholesterol.
Strategic Importance for Merck
The approval provides Merck with a crucial new revenue source as it prepares for the patent expiration of its blockbuster cancer drug, Keytruda, starting in 2028. The loss of patent protection will expose Keytruda to competition from lower-cost biosimilar versions, making the successful launch of new products like Lipfendra essential for the company's long-term financial health.
Market Landscape and Pricing
Lipfendra, also known as enlicitide, enters a market of advanced cholesterol treatments dominated by injectable PCSK9 inhibitors. The drug works by blocking the PCSK9 protein, which regulates cholesterol levels in the blood, a different mechanism from widely used statins that inhibit an enzyme in the liver.
AdMerck told Reuters that the list price for Lipfendra will be $10.50 per day, based on a 30-day supply. The drug's oral administration and pricing will be key factors in its competition against established injectable options.
Market Reaction
Investors responded positively to the regulatory milestone. Following the announcement, shares of Merck rose 1.1% in premarket trading on Thursday.
Read next
More on Stocks
CIBC Offers Compelling Value Profile Among Major Canadian Banks
While TD Bank trades at the lowest price-to-earnings multiple, an analysis of yield and upside potential positions Canadian Imperial Bank of Commerce (CIBC) as a more balanced value investment among its peers.
Volvo Cars Appoints Klaus Zellmer as Next CEO to Succeed Hakan Samuelsson
Volvo Cars has named Klaus Zellmer as its next president and chief executive officer, replacing the departing Hakan Samuelsson. The transition comes as the automaker pursues an aggressive growth strategy amid market challenges.
Analyst 'Strong Buy' Ratings Signal Upside for TSX-Listed Miners
Several Canadian gold and copper miners, including Equinox Gold and Kinross Gold, are attracting strong buy ratings from analysts who project double-digit upside potential based on recent company-specific catalysts.
Saudi Tadawul All Share Index Slips to 1-Month Low on Broad Sector Declines
Saudi Arabia's benchmark stock index, the Tadawul All Share, closed down 0.26% on Sunday to reach its lowest point in a month, dragged lower by weakness in the insurance and energy sectors.